reason report
bottom line reiter op rate even higher
convict pt print solid across
board absolut red flag though commentari medicar
sander propos weigh broadli name healthcar
servic sector whole rais ep back
quarter guidanc rais
compar guidanc midpoint also rais ep
reflect increas baselin within
growth guidanc dmg close pois offer
annual ep upsid upon close clearli hh chang around
drug price reform impact lead
move rebat po commerci plan particip
part demonstr pilot commenc
diversifi busi model reli drug manufactur
rebat commerci tx lawsuit also materi
fundament impact given exit exchang
exposur medicaid expans optum differenti
platform address fraud abus clinic wast also
lever nice healthcar deliveri system ambulatori
optum platform risk/reward investor small
probabl unlik medicar outcom across fiscal
polit legisl suppli chain disrupt labor market hurdl
conserv least better optum almost
earn even uhc statutori reserv organ cash flow
gener excess parent cash reduc downsid
risk upsid pt trade level potenti
legisl delay obamacar hipf key catalyst
drive earn upsid drive
multipl expans quell fear potenti medicar
propos well ahead elect
beat rais across dimens red flag
ep beat revenu beat beat bp sg beat
bp partial off-set bp tax rate miss dcp flat
day cfo guidanc re-affirmed despit season weaker cfo ni
medic cost trend well control prior year favor reserv
develop mm driven uhc rather optum
base price-to-earnings averag
ep
net debt total capit
price-to-earnings lt ep growth
estimate lt ep growth compound-annual-growth-rate
year price history/av daili volume mil
compani inform svb leerink llc research
revenu billion ep dilut show ep exclud non-cash amort year quarterli number
may sum full-year number due round
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rais ep back solid
ep rais midpoint new guidanc rang
ep given fewer weekend per cfo guidanc ep view
remain essenti unchang dmg close pois offer
annual ep upsid depend upon time close
increment commentari offer ftc review also
rais ep ep growth normal
growth rang top-lin growth high singl digit annual
optum rx continu adjust busi model reflect drug
price reform chang link link link link link
rebat pass medicar part particip
demonstr pilot transfer rebat po
commerci busi model increasingli diversifi across
multipl driver reli rebat bottom line per
commentari manag call optum rx remain competit
first-mov integr busi employ mapd pbm
sell season remain competit health plan segment
medicar advantag growth remain solid even though
brisk uhc chalk win medicaid
contract nc az contract expect seek
smaller region health plan asset select market uhc exit iowa
rate pressur continu margin remain unsustain
medicar propos weigh stock
driven sell-off across group servic whole ceo
wichmann highlight valu current model public-priv
partnership rel singl payor system see strong
buy opportun risk/reward skew favor upsid
least better given low probabl propos becom
realiti across legisl polit fiscal suppli chain disrupt labor
optum close earn stream even ex
uhc earn optum across ambulatori
optum platform prefer capit deploy shift mix
lower cost site servic optum insight drive value-bas care
administr solut health system risk bear entiti
independ health plan busi ralli individu
record drive domin digit front
balanc sheet strong ratio dtc cfo
offer comfort valu investor look step
front elect populist campaign messag side
aisl organ flow gener statutori reserv excess
parent cash offer back-stop valu investor
beyond event remot materi ever exhibit
pt offer upsid rare opportun
see final part propos may like probabl
legisl hipf delay past catalyst year pt
contempl price-to-earnings averag ep
reiter op rate even higher convict pt unh print
solid across board absolut red flag though commentari medicar
sander propos weigh broadli name healthcar servic sector whole
rais ep back quarter guidanc rais
compar guidanc midpoint also rais ep
reflect increas baselin within growth
guidanc dmg close pois offer annual ep upsid depend
upon time close reiter month pt price-to-earnings
averag ep see sell-off strong buy opportun
clearli hh chang around drug price reform impact
lead move rebat po commerci plan particip part
demonstr pilot commenc diversifi busi model reli
drug manufactur rebat commerci tx lawsuit also materi
fundament impact given exit exchang exposur
medicaid expans optum differenti platform address fraud abus
clinic wast system healthcar economi also lever nice
healthcar deliveri system ambulatori optum platform risk/reward
investor small probabl unlik medicar outcom across fiscal
polit legisl suppli chain disrupt labor market hurdl conserv least
better optum almost earn even uhc statutori reserv
organ cash flow gener excess parent cash reduc downsid risk
upsid pt trade level potenti legisl delay
obamacar hipf key catalyst drive earn upsid
drive multipl expans quell fear potenti medicar
propos well ahead elect
beat rais across dimens red flag ep beat revenu beat
beat bp sg beat bp partial off-set bp tax rate miss
dcp flat day cfo guidanc re-affirmed despit season weaker cfo ni
medic cost trend well control prior year favor reserv develop
mm beat driven uhc rather optum though optum remain solid
unitedheatlhgroup metricsreport leerink estimatesconsensu estimatesreport sequenti bp report yoy bp metricsconsolid oper oper oper tax cost day cfo/net membership leerink estimatesconsensu estimatesreport sequentialreport servedcommerci medicar public medic part leerink consensu estim commerci risk-bas includ individu group inc
much weaker op profit contribut
includ individu fi member
rais ep back solid ep rais midpoint
new guidanc rang ep given fewer weekend per cfo guidanc
ep view remain essenti unchang dmg close pois offer
annual ep upsid depend upon time close increment
commentari offer ftc review also rais ep ep
growth normal growth rang top-lin growth high singl digit
rais estim
svb leerinkconsensusrevenu amort earn earn weighted-avg share net net ep excl amort flow oper paid repurchas expenditur guidanc earn consensussvb leerink newsvb leerink oldconsensussvb leerink newsvb leerink oldconsensussvb leerink newsvb leerink unitedhealth group inc
optum rx continu adjust busi model reflect drug price reform chang
link rebat pass medicar part particip
demonstr pilot transfer rebat po commerci busi model
increasingli diversifi across multipl driver reli rebat bottom
line per commentari manag call optum rx remain competit first-mov
integr busi employ mapd pbm sell season remain competit
health plan segment
pbm exec showcas valu prop senat hear hh propos remain focu link
hous insulin hear follow suit congress/ hh court link
azar doubl part rule increasingli like link
margin expand yoy optum optum insight optum growth remain impress
rebat pass medicar part
medicar advantag growth remain solid even though brisk
uhc chalk win medicaid contract nc az contract
expect seek smaller region health plan asset select market uhc exit iowa rate
pressur continu margin remain unsustain
segment oper marginsoptum healthoptum insightoptum rxwe also focus drive transpar busi model revenu come administr fee valu share mechan align us consum client need context see time minim impact margin look rebat discount manag overal rebat exist prescript manag gener rebat brand subset rebat drug look medicar market today none valu manag discount rebat held us pass client fulli disclos pass medicaid market within total client base discount pass client john princ ceo-optumrx inc call group inc
medicar propos weigh stock driven sell-off across
group servic whole ceo wichmann highlight valu current model
public-priv partnership rel singl payor system see strong
buy opportun risk/reward skew favor upsid least better given
low probabl propos becom realiti across legisl polit fiscal suppli chain
disrupt labor market impact
manag highlight valu current model public-priv partnership rel
optum close earn stream even ex uhc
earn optum across ambulatori optum platform prefer capit deploy
shift mix lower cost site servic optum insight drive value-bas care
administr solut health system risk bear entiti independ
know public discuss medicar propos view discuss first prism mission individu better serv health system work better perspect welcom contrast propos kind real progress talk call discuss novemb confer found durabl modern inform technolog clinic capabl wholesal disrupt american health care discuss propos would sure jeopard relationship peopl doctor destabil nation health system limit abil clinician practic medicin best inher cost burden would sure sever impact economi job without fundament increas access care path forward achiev univers coverag could substanti reach exist public privat platform david scott wichmann ceo inc call group inc
optum insight backlog remain strong grew yoy
optum health serv mm consum end
optumrx tradit pbm
briova avella genoa moder specialti drug spend expect make
drug spend
optum seek reinvent local deliveri
optum continu grow
balanc sheet strong ratio debt cap cfo
offer comfort valu investor look step front elect populist
campaign messag side aisl organ flow gener statutori reserv
excess parent cash offer back-stop valu investor beyond
event remot materi ever
today serv million patient across approxim health plan payer year virtual everi local optumcar practic particip advanc value-bas care arrang andrew philip witti ceo-optum inc callour clinic team continu advanc perform physician deliv better qualiti outcom senior serv advanc value-bas arrang receiv star rate four star higher deliv lower cost practic serv medicar advantag particip much lower cost origin medicar lower typic medicar advantag higher satisfact np philip witti ceo-optum inc call unitedhealth group inc
debt capit current
gener plenti cfo invest growth
pt offer upsid rare opportun see final part
propos may like probabl legisl hipf delay past catalyst
year pt contempl price-to-earnings averag ep
trade price-to-earnings consensu ep estim
manag prepar hipf return
rel ntm p/efe val pe mean ntmafe val pe mean ntmafe val pe mean ntmafe val pe mean ntmastandard deviat pleas growth year first quarter posit said look long term view expect potenti headwind return tax see rate encourag rate improv seen sinc advanc notic point still enough cover expect return health insur tax think pressur point industri wide say unitedhealthcar particular like said went market long term view expect headwind thought disciplin intend approach goal keep benefit margin stabl possibl despit headwind time drive continu growth like demonstr cours last five six year improv oper earn overal formula execut success intend optimist outlook posit end first quarter thompson ceo-medicar retir inc call group inc
incom servic oper costsmed product oper incom incom earn growth net share dilut earn per ep ep chang growth sg ratio oper group inc
care risk-bas risk-bas advantag medicar public servic medic part prescript drug group inc
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings averag ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base absolut price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
price target base price-to-earnings averag ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
integr regulatori risk across merg ci esrx
pt contempl price-to-earnings averag ep
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
pt contempl price-to-earnings consensu price-to-earnings
ep
underwrit risk aet asset trade peak margin commerci fulli
insur though medacorp commerci broker price survey give us confid
price environ remain appropri hard offer flat even potenti
modestli expand underwrit margin risk potenti futur margin compress
aet health insur even meaning given associ neg impact
debt ebitda load compani need focus debt
pay next month departur shawn guertin aet cfo
slate becom cfo make us less confid price postur
health insur book commenc new bulk compet
share gain commerci medicar advantag market
macroeconom risk risk macroeconom downturn higher
defens pbm sub sector given cyclic correl retail front store
sale employ data
regulatori risk convinc pbm add valu earn
low probabl threat potenti drug manufactur rebat elimin off-set
new busi model includ administr fee and/or perform guarante
expos pbm retail pharmaci busi compar
player pbm risk
execut integr risk face greater risk well given integr
pbm broader organ also transform agenda around
build retail front model amid risk leverag balanc sheet
e-commerce/amzn greater exposur eros sale on-line
channel well given exposur retail front store retail pharmaci e-
commerc though larg price retail multipl expect less like
pursu agenda becom pbm given associ integr clinic evid
base treatment guidelin integr provid network domin captiv pbm
model mega deal
remain posit reiter op rate month pt
contempl price-to-earnings averag ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yet yield adequ
return capit
sotp valuat point per share expect premium toward much
potenti takeout price per share see like buyer light
synergi medicaid complet pbm across ingeniorx optum rx
optum rx seek specialti rx expect look region player shore
medicaid pois well build third-parti servic platform best
place well pay cash also like interest given medicaid focu strategi
bring pbm in-hous would like pay asset equiti rather cash
delev fide transact financi buyer also like suitabl strateg
buyer identifi
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
pt contempl multipl averag
ep may day dive top-lin growth continu margin expans
 strategi may import posit catalyst
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
averag cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
averag ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
